LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.
- 100% patient satisfaction with SPONTAN nasal spray in post-prostatectomy ED
- All patients preferred SPONTAN over traditional oral ED treatments
- Large global market with ~8,500 prostatectomies annually in Australia alone
- Clinical validation presented at Asia-Pacific Prostate Cancer Conference
- SPONTAN advancing through late-stage development and regulatory pathways
Clinical Breakthrough in Post-Prostatectomy ED Treatment
LTR Pharma Limited (ASX, LTP) has announced compelling clinical outcomes for its intranasal erectile dysfunction therapy, SPONTAN, following radical prostatectomy. Presented at the 25th Asia-Pacific Prostate Cancer Conference in Sydney, a case series involving four patients demonstrated 100% satisfaction with SPONTAN, with all participants preferring it over conventional oral PDE5 inhibitors.
This unanimous preference highlights SPONTAN’s key advantages, rapid onset and ease of use, which address the common patient frustrations of spontaneity and tolerability that often lead to discontinuation of oral ED medications.
Addressing a Significant Unmet Need
Erectile dysfunction is a prevalent and persistent side effect for men undergoing radical prostatectomy, with approximately 8,500 such surgeries performed annually in Australia and hundreds of thousands worldwide. Traditional oral therapies frequently fall short, with studies indicating that half of patients discontinue treatment due to dissatisfaction.
SPONTAN’s intranasal delivery platform offers a differentiated approach, enabling a rapid onset of action within 10 minutes, which could redefine patient expectations and improve adherence in this underserved market segment.
Strategic Positioning and Next Steps
LTR Pharma’s Executive Chairman, Lee Rodne, emphasised the transformative potential of SPONTAN for prostate cancer survivors, positioning it as a likely first-line therapy. The company is advancing SPONTAN through late-stage clinical development and regulatory pathways in Australia, the US, and other key markets.
Currently available under Australia’s Special Access Scheme, SPONTAN is also paving the way for the US launch of ROXUS, a related intranasal ED therapy, under a personalised healthcare pathway. These initiatives collectively de-risk the product’s commercialisation and regulatory approval prospects.
Broader Pipeline and Market Implications
Beyond SPONTAN, LTR Pharma is developing OROFLOW, an intranasal spray targeting oesophageal motility disorders, further expanding its footprint in innovative intranasal therapies. The company’s proprietary delivery platform and strategic partnerships underpin its ambition to deliver patient-centric treatments that improve quality of life globally.
While the case series is small, the positive patient feedback and clinical validation at a leading regional forum underscore SPONTAN’s potential to disrupt the ED treatment landscape, particularly for post-prostatectomy patients.
Bottom Line?
SPONTAN’s strong patient preference and clinical validation mark a pivotal step toward reshaping post-prostatectomy ED treatment and unlocking significant market potential.
Questions in the middle?
- Will larger clinical trials confirm SPONTAN’s efficacy and patient preference?
- What are the timelines and hurdles for regulatory approvals in the US and other markets?
- How will SPONTAN’s pricing and reimbursement strategies impact market adoption?